Login / Signup

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.

Manon BelhassenFaustine DalonMaëva NolinEric Van Ganse
Published in: Respiratory research (2021)
This observational study identified potential differences in outcome under newly prescribed antifibrotic drugs, deserving further explorations.
Keyphrases
  • idiopathic pulmonary fibrosis
  • interstitial lung disease
  • pulmonary fibrosis
  • human health
  • type diabetes
  • metabolic syndrome
  • risk assessment
  • climate change
  • weight loss
  • systemic sclerosis